Comparison of a commercial Varicella Zoster glycoprotein IgG enzyme immunoassay with a reference time resolved fluorescence immunoassay (VZV TRFIA) for measuring VZV IgG in sera from pregnant women, sera sent for confirmatory testing and pre and post vOka vaccination sera from healthcare workers

Journal of Clinical Virology

Volumn 53, Issue 3, 2012, Pages 201-207

  Maple, P A C ^a   Breuer, J ^b   Quinlivan, M ^b   Kafatos, G ^a   Brown, K E ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

VOka vaccination; VZV glycoprotein IgG EIA; VZV time resolved fluorescence immunoassay

Indexed keywords

HERPES ZOSTER IMMUNOGLOBULIN; VARICELLA ZOSTER VACCINE;

ADULT; ARTICLE; BLOOD ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME IMMUNOASSAY; FEMALE; HEALTH CARE PERSONNEL; HERPES ZOSTER; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REFERENCE TIME RESOLVED FLUORESCENCE IMMUNOASSAY; SENSITIVITY AND SPECIFICITY; VACCINATION; VARICELLA ZOSTER GLYCOPROTEIN IMMUNOGLOBULIN G ENZYME IMMUNOASSAY; VARICELLA ZOSTER VIRUS;

ANTIBODIES, VIRAL; CHICKENPOX; CHICKENPOX VACCINE; COHORT STUDIES; FEMALE; FLUOROIMMUNOASSAY; HEALTH PERSONNEL; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; PREGNANCY; REGRESSION ANALYSIS; VIRAL ENVELOPE PROTEINS;

EID: 84856972670     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.12.010     Document Type: Article

References (23)

1. Arvin A.M. Varicella-Zoster virus. Clin Microbiol Rev 1996, 9:361-381.
2. Tunbridge A.J., Breuer J., Jeffery K.J. British Infection Society. Chickenpox in adults - clinical management. J Infect 2008, 57:95-102.
3. Rawson H., Crampin A., Noah N.H. Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ 2001, 323:1091-1093.
4. Daley A.J., Thorpe S., Garland S.M. Varicella and the pregnant woman: prevention and management. Aust N Z J Obstet Gynaecol 2008, 48:26-33.
5. Joint Committee of Vaccination and Immunisation Immunisation against infectious disease 2006, Department of Health.
6. Takahashi M. Current status and prospects of live varicella vaccine. Vaccine 1992, 10:1007-1014.
7. Schmid D.S., Jumaan A.O. Impact of varicella vaccine on Varicella-Zoster virus dynamics. Clin Microbiol Rev 2010, 23:202-217.
8. Pinot de Moira A., Nardone A., ESEN2 group Varicella zoster virus vaccination policies and surveillance strategies in Europe. Euro Surveill 2000, 10:43-45.
9. Arvin A.M. Varicella vaccine - the first six years. N Engl J Med 2001, 344:1007-1009.
10. Ndumbe P.M., Cradock-Watson J., Levinsky R.J. Natural and artificial immunity to Varicella Zoster virus. J Med Virol 1988, 25:171-178.
11. Provost P.J., Krah D.L., Kuter B.J., Morton D.H., Schofield T.L., Wasmuth E.H., et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 1991, 9:111-116.
12. Maple P.A.C., Gray J., Breuer J., Kafatos G., Parker S., Brown D. Performance of a time-resolved fluorescence immunoassay for measuring Varicella-Zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay. Clin Vaccine Immunol 2006, 13:214-218.
13. Chris Maple P.A., Gray J., Brown K., Brown D. Performance characteristics of a quantitative, standardised varicella zoster IgG time resolved fluorescence immunoassay (VZV TRFIA) for measuring antibody following natural infection. J Virol Methods 2009, 157:90-92.
14. Maple P.A.C., Rathod P., Smit E., Gray J., Brown D., Boxall E.H. Comparison of the performance of the LIAISON VZV-IgG and VIDAS automated enzyme linked fluorescent immunoassays with reference to a VZV-IgG time-resolved fluorescence immunoassay and implications of choice of cut-off for LIAISON assay. J Clin Virol 2009, 44:9-14.
15. Boxall E.H., Maple P.A.C., Rathod P., Smit E. Follow-up of pregnant women exposed to chicken pox: an audit of relationship between level of antibody and development of chicken pox. Eur J Clin Microbiol Infect Dis 2011, 30:1193-1200.
16. McDonald S.L.R., Maple P.A.C., Andrews N., Brown K.E., Ayres K.L., Scott F.T., et al. Evaluation of the time resolved fluorescence immunoassay (TRFIA) for the detection of varicella zoster virus (VZV) antibodies following vaccination of healthcare workers. J Virol Methods 2011, 172:60-65.
17. Chris Maple P.A., Gunn A., Sellwood J., Brown D.W.G., Gray J.J. Comparison of fifteen commercial assays for detecting varicella zoster virus IgG with reference to a time resolved fluorescence immunoassay (TRFIA) and the performance of two commercial assays for screening sera from immunocompromised individuals. J Virol Methods 2009, 155:143-149.
18. Sauerbrei A., Wutzler P. Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen. J Clin Microbiol 2006, 44:3094-3097.
19. Sauerbrei A., Wutzler P. Serological detection of specific IgG to varicella-zoster virus by novel ELISA based on viral glycoprotein antigen. Clin Lab 2009, 55:1-7.
20. Breuer J., Schmid D.S., Gershon A.A. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccines and to screen for susceptibility to varicella. JID 2008, 197(Suppl. 2):S147-S151.
21. Krah D.L. Assays for antibodies to varicella-zoster virus. Infect Dis Clin North Am 1996, 10:507-526.
22. Wasmuth E.H., Miller W.J. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 1990, 32:189-193.
23. Hammond O., Wang Y., Green T., Antonello J., Kuhn R., Motley C., et al. The optimization and validation of the glycoprotein ELISA assay for quantitative Varicella-Zoster virus (VZV) antibody detection. J Med Virol 2006, 78:1679-1687.